
Annual report 2024
added 01-17-2026
Trinity Biotech plc EPS Ratio 2011-2026 | TRIB
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Quarterly EPS Ratio Trinity Biotech plc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.8 | - | - | - | 4.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.1 | 2.8 | 3.45 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
Anixa Biosciences
ANIX
|
-0.34 | $ 3.01 | -2.9 % | $ 97.7 K | ||
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-0.23 | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
Brainsway Ltd.
BWAY
|
-0.24 | $ 23.56 | -2.04 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 33.99 | 0.65 % | $ 366 M | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
BioNano Genomics
BNGO
|
-88.1 | $ 1.38 | -6.12 % | $ 1.75 M | ||
|
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 39.01 | -0.38 % | $ 1.08 B | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
-1.2 | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
5.33 | $ 218.94 | -0.24 % | $ 160 B | ||
|
Exact Sciences Corporation
EXAS
|
-4.67 | $ 102.48 | 0.18 % | $ 19 B | ||
|
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | ||
|
Fulgent Genetics
FLGT
|
-1.41 | $ 26.01 | -0.88 % | $ 786 M | ||
|
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | ||
|
Guardant Health
GH
|
-3.56 | $ 111.89 | 1.28 % | $ 13.7 B | ||
|
DexCom
DXCM
|
1.4 | $ 73.26 | -1.0 % | $ 28.3 B | ||
|
CareDx, Inc
CDNA
|
-3.54 | $ 20.4 | -1.92 % | $ 1.1 B | ||
|
Celcuity
CELC
|
-2.83 | $ 109.94 | -1.94 % | $ 4.34 B | ||
|
DarioHealth Corp.
DRIO
|
1.93 | $ 10.95 | 6.31 % | $ 311 M | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
4.52 | $ 65.82 | -1.3 % | $ 4.55 B | ||
|
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-7.69 | $ 145.95 | -2.5 % | $ 23.2 B | ||
|
QIAGEN N.V.
QGEN
|
0.38 | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
7.57 | $ 230.03 | -2.31 % | $ 41.7 B | ||
|
NeoGenomics
NEO
|
-0.62 | $ 11.85 | -4.44 % | $ 1.5 B | ||
|
Charles River Laboratories International
CRL
|
0.2 | $ 210.0 | -0.83 % | $ 10.8 B | ||
|
Medpace Holdings
MEDP
|
13.1 | $ 583.39 | -1.63 % | $ 18.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
7.78 | $ 184.82 | 1.37 % | $ 20.5 B | ||
|
Biodesix
BDSX
|
-0.33 | $ 8.94 | -7.45 % | $ 1.16 B | ||
|
Personalis
PSNL
|
-1.37 | $ 9.4 | -5.72 % | $ 557 M | ||
|
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | ||
|
Precipio
PRPO
|
-4.51 | $ 24.39 | 0.54 % | $ 31.7 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.89 | $ 269.39 | -0.16 % | $ 22.6 B | ||
|
Mettler-Toledo International
MTD
|
40.7 | $ 1 384.16 | -0.62 % | $ 29.4 B | ||
|
ICON Public Limited Company
ICLR
|
9.6 | $ 179.07 | -3.67 % | $ 14.8 B | ||
|
IDEXX Laboratories
IDXX
|
10.8 | $ 674.78 | -0.29 % | $ 55.6 B | ||
|
Koninklijke Philips N.V.
PHG
|
3.67 | $ 28.73 | -1.79 % | $ 20 B | ||
|
Agilent Technologies
A
|
3.98 | $ 132.75 | -0.37 % | $ 40.4 B | ||
|
Biomerica
BMRA
|
-2.16 | $ 2.39 | 0.21 % | $ 5.49 M |